皇冠开户
热门标签

哈希定位胆(www.hx198.vip):Sanofi ends cancer drug trials

时间:3周前   阅读:1   评论:6

皇冠信用网开户www.hg108.vip)是一个开放皇冠正网即时比分、皇冠信用网开户的平台。皇冠信用网开户平台(www.hg108.vip)提供最新皇冠登录,皇冠APP下载包含新皇冠体育代理、会员APP,提供皇冠信用网代理开户、皇冠信用网会员开户业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

哈希定位胆www.hx198.vip)采用波场区块链高度哈希值作为统计数据,游戏数据开源、公平、无任何作弊可能性,开放单双哈希、幸运哈希、哈希定位胆、哈希牛牛等游戏。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:Allbet注册(www.aLLbet8.vip):New EPF member registration up to 146,000 in first quarter of 2022

下一篇:tài xỉu online(www.84vng.com):Lào công bố danh sách triệu tập cho AFF Cup 2022, không có Billy Ketkeophomphone

网友评论

  • 2022-09-07 00:35:47

    High-growth and technology stocks such as Apple Inc and Microsoft Corp rose in trading before the bell.不错一直在看。

  • 2022-09-18 01:23:28

    “For now, we keep our ‘outperform’ call on Genting unchanged, pending its 2Q22 results later this month-end,” said Kenanga Research in a report. It has a RM5.86 target price for Genting.哈哈,别忘了读者